{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-021205","form_type":"8-K","ticker":"ADTX","cik":"0001726711","company_name":"Aditxt, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.634405+00:00","generated_at":"2026-05-25T06:48:42.659340+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aditxt settles Aldevron dispute with $1.8M; Adimune ships ADI-100 drug substances","bullets":["Settlement with Aldevron: pays $1M cash and issues $824,371.06 promissory note due May 16, 2025, with 1.5% interest if unpaid.","Adimune subsidiary begins shipment of GMP clinical-grade drug substances for final formulation of ADI-100.","Preclinical data: no toxicity, no antibody formation, no organ persistence; immune system not impaired.","Clinical trials planned in Germany (psoriasis, Type 1 Diabetes) and at Mayo Clinic (Stiff Person Syndrome).","Pre-IND meeting with FDA expected Q2 2025; German regulatory pre-submission meetings completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-021205","json":"https://secwatch.observer/filing/0001213900-25-021205.json","markdown":"https://secwatch.observer/filing/0001213900-25-021205.md","text":"https://secwatch.observer/filing/0001213900-25-021205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025021205/0001213900-25-021205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025021205/ea0233377-8k_aditxt.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T06:48:42.659340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e29ad55ff949bbeb285382755cd834df00f5a125","claim":"Aditxt, Inc. incurred loan of $824,371.06 with Aldevron, LLC at 1.5% per annum maturing May 16, 2025.","evidence_excerpt":"Pursuant to the Settlement Agreement, the Company will pay $1 million and issue a Promissory Note (the “Note”) in the principal amount of $824,371.06 (the “Principal Amount”). The Principal Amount will not bear interest unless it is not repaid in full by its maturity date on May 16, 2025, in which case interest will accrue at a rate of one and one-half percent (1.5%) per annum.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390025021205/0001213900-25-021205-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$824,371.06"},{"label":"Counterparty","value":"Aldevron, LLC"},{"label":"Rate","value":"1.5% per annum"},{"label":"Maturity","value":"May 16, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}